Harvard Bioscience Announces Creation of Scientific Advisory Board
Key Highlights
- ➤Harvard Bioscience creates five-member Scientific Advisory Board
- ➤Board will guide research, development, and new product roadmaps
- ➤SAB will meet quarterly to influence R&D and product launches
- ➤Members bring expertise in drug discovery and translational medicine
Expert Statements
John Duke, President and CEO of Harvard Bioscience
“The formation of our Scientific Advisory Board marks an exciting chapter for Harvard Bioscience”
John Duke, President and CEO of Harvard Bioscience
“It brings together distinguished industry leaders to influence our R&D and new product roadmaps.”
John Duke, President and CEO of Harvard Bioscience
“The combined expertise in drug discovery, translational medicine, and launching new products will be instrumental in maximizing value for our customers and shareholders.”
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company’s ongoing research, development, and new product roadmaps. The SAB will meet quarterly and consists of five members, Harvard Bioscience President and CEO John Duke and four experienced industry leaders.
"The formation of our Scientific Advisory Board marks an exciting chapter for Harvard Bioscience," said John Duke, President and CEO of Harvard Bioscience. "It brings together distinguished industry leaders to influence our R&D and new product roadmaps. The combined expertise in drug discovery, translational medicine, and launching new products will be instrumental in maximizing value for our customers and shareholders."
Get started
Create a free account to read the full story.